Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruix J.Qin S.Merle P.Granito A.Huang Y.-H.Bodoky G.Pracht M.Yokosuka O.Rosmorduc O.Breder V.Gerolami R.Masi G.Ross P.J.Song T.Bronowicki J.-P.Ollivier-Hourmand I.Kudo M.ANN-LII CHENGLlovet J.M.Finn R.S.LeBerre M.-A.Baumhauer A.Meinhardt G.Han G.2021-08-312021-08-3120170140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007560261&doi=10.1016%2fS0140-6736%2816%2932453-9&partnerID=40&md5=4fce0d12285de29c5e7439f27252887bhttps://scholars.lib.ntu.edu.tw/handle/123456789/580108Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialjournal article10.1016/S0140-6736(16)32453-9279322292-s2.0-85007560261